Next-Gen Parasiticides

About Zoetis

Zoetis is the global leader in animal health, with a $50.57B market valuation and 2024 revenue of $9.3B. The company operates a diversified, two-segment model (Livestock and Companion Animal) and is distinguished by its deep R&D pipeline and commercial scale. Its strategy is centered on a 'Continuum of Care' approach—predicting, preventing, detecting, and treating disease—supported by significant investments in monoclonal antibodies, diagnostics, and digital technologies to drive durable growth.

About Elanco

Elanco is a publicly traded, global animal health leader with a $11.73B market cap, spun off from Eli Lilly in 2018. The company's mission, 'making life better for animals, makes life better,' is executed through a dual-pillar strategy focusing on high-growth companion animal health and productivity-enhancing farm animal solutions. Its achievements include a robust portfolio of market-leading brands like Credelio and Seresto, a global commercial footprint, and a commitment to a consistent flow of innovation. Elanco's strategy leverages its integrated technology platforms and digital transformation initiatives to drive sustainable growth and address global challenges like food security and the human-animal bond.

Therapeutic Areas